Transplant-associated thrombotic microangiopathy is a rare but often devastating complication. The biology of this interesting entity is just being unraveled. In a Blood Advances Talk, Christopher Dvorak discusses the biology, diagnosis, and treatment of this entity in detail.
Metabolic syndrome increases risk of venous thromboembolism recurrence after acute deep vein thrombosis
Recurrence of venous thromboembolism (VTE) is a common clinical occurrence, and identifying patients who are at high risk for the condition is of major importance when decisions of duration of anticoagulation are considered. Stewart and Kline explored the impact of metabolic syndrome on VTE recurrence risk and reached important clinical findings.
Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia
In this issue’s Testing Advances article, Harvey and Tasian explore the available clinical diagnostics and treatment strategies for the care of patients with Philadelphia chromosome–like acute lymphoblastic leukemia. We hope you find this article useful in your care of this challenging disease.
An update on the molecular pathogenesis and potential therapeutic targeting of AML with t(8;21)(q22;q22.1); RUNX1-RUNX1T1
In this issue, Al-Harbi and colleagues review the pathogenesis and therapeutic options for patients with acute myeloid leukemia (AML) harboring the t(8;21) chromosomal translocation. The authors discuss in detail the unique features of this subtype of leukemia that is often associated with a favorable outcome.
Refined National Institutes of Health response algorithm for chronic graft-versus-host disease in joints and fascia
Patients with chronic graft-vs-host disease (cGVHD) have pleiotropic clinical features. To provide a framework for the diagnosis and response assessment of these patients, experts have developed the National Institutes of Health criteria. Inamoto and colleagues developed a refinement in the response algorithm for patients with cGVHD involving the joints and fascia.
The treatment of patients with chronic myelogenous leukemia (CML) has been revolutionized by the development of tyrosine kinase inhibitors (TKIs). However, the choice of which TKI and the best strategy to accomplish long-term control of the disease is a matter of ongoing debate. Baccarani and colleagues present a proposal for achieving treatment-free remission on behalf of the GIMEMA CML Working Party.